StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT - Free Report) from a sell rating to a hold rating in a report issued on Sunday.
Separately, HC Wainwright reissued a buy rating and set a $11.00 target price on shares of Galectin Therapeutics in a research report on Friday, August 16th.
Read Our Latest Research Report on GALT
Galectin Therapeutics Stock Performance
Galectin Therapeutics stock traded up $0.10 during trading on Friday, reaching $2.82. 408,349 shares of the company's stock were exchanged, compared to its average volume of 116,462. Galectin Therapeutics has a 52-week low of $1.55 and a 52-week high of $4.27. The firm has a market cap of $175.63 million, a price-to-earnings ratio of -3.81 and a beta of 0.61. The company's 50-day moving average is $2.51 and its two-hundred day moving average is $2.72.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.04). Analysts anticipate that Galectin Therapeutics will post -0.79 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of GALT. Commonwealth Equity Services LLC increased its holdings in Galectin Therapeutics by 317.6% in the second quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company's stock valued at $1,092,000 after buying an additional 367,610 shares during the last quarter. Wealthspire Advisors LLC increased its holdings in shares of Galectin Therapeutics by 116.7% in the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company's stock worth $952,000 after acquiring an additional 214,512 shares during the period. Sanctuary Advisors LLC bought a new stake in Galectin Therapeutics in the 2nd quarter valued at about $227,000. Bank of New York Mellon Corp acquired a new stake in shares of Galectin Therapeutics in the second quarter valued at approximately $146,000. Finally, Vanguard Group Inc. boosted its position in shares of Galectin Therapeutics by 2.0% during the first quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company's stock worth $4,732,000 after buying an additional 38,037 shares during the period. Hedge funds and other institutional investors own 11.68% of the company's stock.
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Further Reading
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
